Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis | Zendy

George Dranitsaris | Zendy; Carlo DeAngelis | Zendy; Blake Pearson | Zendy; Laura McDermott | Zendy; Bernd PohlmannEden | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis

Author(s) -

George Dranitsaris,

Carlo DeAngelis,

Blake Pearson,

Laura McDermott,

Bernd PohlmannEden

Publication year - 2021

Publication title -

applied health economics and health policy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.099

H-Index - 40

eISSN - 1179-1896

pISSN - 1175-5652

DOI - 10.1007/s40258-021-00638-4

Subject(s) - oxycodone , hydrocodone , pregabalin , medicine , hydromorphone , cannabis , opioid , tramadol , gabapentin , oxymorphone , legalization , medical prescription , codeine , anesthesia , morphine , psychiatry , pharmacology , analgesic , alternative medicine , receptor , pathology

On 17 October 2018 recreational cannabis became legal in Canada, thereby increasing access and reducing the stigma associated with its use for pain management. This study assessed total opioid prescribing volumes and expenditures prior to and following cannabis legalization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research